[go: up one dir, main page]

NO20062928L - Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon - Google Patents

Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon

Info

Publication number
NO20062928L
NO20062928L NO20062928A NO20062928A NO20062928L NO 20062928 L NO20062928 L NO 20062928L NO 20062928 A NO20062928 A NO 20062928A NO 20062928 A NO20062928 A NO 20062928A NO 20062928 L NO20062928 L NO 20062928L
Authority
NO
Norway
Prior art keywords
formula
compounds
compound
administering
methods
Prior art date
Application number
NO20062928A
Other languages
English (en)
Inventor
Milind Deshpande
Dawei Chen
Andrew Thurkauf
Avinash Phadke
Shouming Li
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of NO20062928L publication Critical patent/NO20062928L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer forbindelser med formel: (1), hvor variablene Ar, A1 A2, A3, A4, R5, R6, R7, V, W, X og Y er som definert heri. Visse forbindelser med formel (1) beskrevet heri har potent antiviral aktivitet. Oppfinnelsen tilveiebringer også forbindelser med formel (1) som er potente og/eller selektive inhibitorer av hepatitt C virusreplikasjon. Oppfinnelsen tilveiebringer videre farmasøytiske sammensetninger inneholdende en eller flere forbindelser med formel (1), eller et salt, solvat eller acylert prodroge av slike forbindelser, og en eller flere farmasøytisk akseptable bærere, eksipienter eller fortynningsmidler. Foreliggende oppfinnelse tilveiebringer også fremgangsmåter for behandling av pasienter som lider av visse infeksiøse sykdommer ved administrering til slike pasienter en mengde av en forbindelse ifølge formel (1) som er effektiv for å redusere tegn eller symptomer på sykdom. Disse infeksiøse sykdommene inkluderer virale infeksjoner, spesielt HCV-infeksjoner. Oppfinnelsen tilveiebringer videre fremgangsmåter for behandling av humane pasienter som lider av en infeksjonssykdom, men omfatter også fremgangsmåter for behandling av andre dyr, inkludert buskap og husdyr, som lider av en infeksiøs sykdom. Fremgangsmåter for behandling inkluderer administrering av en forbindelse ifølge formel (1) som et enkelt aktivt middel eller administrering av en forbindelse ifølge formel (1) i kombinasjon med en eller flere andre terapeutiske midler.
NO20062928A 2004-01-06 2006-06-22 Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon NO20062928L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53483904P 2004-01-06 2004-01-06
PCT/US2005/000339 WO2005067900A2 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
NO20062928L true NO20062928L (no) 2006-08-03

Family

ID=34794326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062928A NO20062928L (no) 2004-01-06 2006-06-22 Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon

Country Status (19)

Country Link
US (1) US7439374B2 (no)
EP (1) EP1709047B1 (no)
JP (1) JP2007517887A (no)
KR (1) KR20060121289A (no)
CN (1) CN1946720A (no)
AP (1) AP2006003659A0 (no)
AR (1) AR047367A1 (no)
AT (1) ATE479684T1 (no)
AU (1) AU2005204369B2 (no)
BR (1) BRPI0506705A (no)
CA (1) CA2552002A1 (no)
DE (1) DE602005023266D1 (no)
EA (1) EA200601281A1 (no)
IL (1) IL176486A0 (no)
NO (1) NO20062928L (no)
NZ (1) NZ548375A (no)
OA (1) OA13357A (no)
TW (1) TW200528459A (no)
WO (1) WO2005067900A2 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008024763A2 (en) * 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7985763B2 (en) * 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
US7897764B2 (en) * 2007-06-08 2011-03-01 National Health Research Institutes Thiourea derivatives
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103467482B (zh) * 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
KR20210141778A (ko) 2016-06-07 2021-11-23 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
EA201992253A1 (ru) 2017-03-23 2020-03-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4828609A (no) 1971-08-23 1973-04-16
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
GB9504460D0 (en) * 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
US6060484A (en) 1996-05-06 2000-05-09 Eli Lilly And Company Anti-viral method
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
KR20050065661A (ko) * 2002-11-01 2005-06-29 비로파마 인코포레이티드 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법
US7094807B2 (en) * 2002-11-19 2006-08-22 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and related compounds; inhibitors of viral replication
MXPA06000418A (es) 2003-07-10 2006-04-05 Achillion Pharmaceuticals Inc Derivados de ariltiourea sustituida utiles como inhibidores de duplicacion viral.

Also Published As

Publication number Publication date
IL176486A0 (en) 2006-10-05
EP1709047B1 (en) 2010-09-01
AU2005204369A1 (en) 2005-07-28
OA13357A (en) 2007-04-13
CA2552002A1 (en) 2005-07-28
AR047367A1 (es) 2006-01-18
US20050228013A1 (en) 2005-10-13
TW200528459A (en) 2005-09-01
NZ548375A (en) 2010-07-30
KR20060121289A (ko) 2006-11-28
EA200601281A1 (ru) 2006-12-29
BRPI0506705A (pt) 2007-05-02
WO2005067900A3 (en) 2005-09-29
JP2007517887A (ja) 2007-07-05
AU2005204369B2 (en) 2010-06-10
ATE479684T1 (de) 2010-09-15
AP2006003659A0 (en) 2006-06-30
US7439374B2 (en) 2008-10-21
WO2005067900A2 (en) 2005-07-28
CN1946720A (zh) 2007-04-11
EP1709047A2 (en) 2006-10-11
DE602005023266D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
NO20062928L (no) Azabenzofuran substituerte tiourear som inhibitorer av viral replikasjon
NO20052546L (no) Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon.
UA92746C2 (en) Thiazole compounds and methods of use
TW200600492A (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
KR101706624B1 (ko) 고병원성 감염성 질환의 예방 및 치료제
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
DK1611088T3 (da) Hydroxymater som terapeutiske midler
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
EA200500583A1 (ru) Ингибиторы белка-регулятора трансмембранной проводимости при муковисцидозе и их применение
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
Alshaeri et al. A contemporary look at COVID-19 medications: available and potentially effective drugs
WO2005095345A3 (en) Heteroaryl guanidines as inhibitors of viral replication
JP2006527185A5 (no)
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MY141506A (en) Virus therapeutic drug
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
CA2512713A1 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
TH82492A (th) ซับสทิทิวเทด แอริล แอซิลไธ โอยูเรียและสารประกอบที่เกี่ยวข้อง; ตัวยับยั้งการถ่ายแบบไวรัส
Waghchaure et al. A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT
US7282599B2 (en) Dithiocarbamate antiviral agents and methods of using same
TW200716629A (en) Pyrazolopyrimidine derivative or pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application